The prognostic negative impact of CDKN2A/B deletion in IDHm astrocytomas with morphological lower-grade features is established and the reason for the molecular criteria of WHO grade 4 astrocytomas [2, 8, 10–12]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).